Patients with type 2 diabetes mellitus (T2DM) and symptomatic coronary artery disease (CAD) treated with metformin fare better with the addition of vildagliptin versus glimepiride, as the former is associated with better glycaemic control and lipid profile, according to a study.
The combination of sodium-glucose co-transporter-2 (SGLT2i) and dipeptidyl peptidase-4 (DPP-4i) inhibitors cuts postprandial hyperglycaemia and improves the quality of glycaemic variability, as opposed to monotherapy with either agent, reports a new study.
The approval of the first COVID-19 vaccine came at a breakneck speed in December. Inoculation started in the US, liberating pent-up hopes that virus-ravaged states could get past the pandemic that has killed over 1.5 million people across continents.
In patients with type 2 diabetes (T2D) and nephrotic-range proteinuria, treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin helps reduce albuminuria burden and manage blood sugar at the same time, without increasing the risk of adverse cardiovascular or kidney events, according to data from the CARMELINA trial.
Body mass index (BMI) levels both above and below 25.0–29.9 kg/m2 are associated with increased mortality in a population without pre-existing disease, suggesting that the current cutoff of overweight (BMI ≥23 kg/m2) may need re-evaluation and that BMI alone may not be an accurate measure for indicating adiposity in Asians, according to a prospective cohort study in Korea.
The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score ≤25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.
Use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor sotagliflozin led to a reduction in the risk of deaths from cardiovascular (CV) causes, hospitalizations for heart failure (HF), and urgent visits for HF compared with placebo among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) regardless of the degree of albuminuria, the SCORED* trial has shown.
Prediabetes contributes to faster functional decline and disability, irrespective of the future development of diabetes, a study suggests. This association is partly mediated by cardiovascular diseases.
Undergoing in-facility physical activity (PA) programmes initiated before the 20th week of gestation helps reduce the risk of developing gestational diabetes mellitus (GDM) among high-risk mothers, according to the results of a meta-analysis.